Wyeth, Advanced Life In Pact To Develop Antibiotic For Southeast Asia
This article was originally published in PharmAsia News
Executive Summary
Wyeth is investing $100 million in a collaboration with Advanced Life Sciences, Holdings, also of the U.S., to develop and market a pneumonia antibiotic for the Asia Pacific region, but excluding Japan. Advanced Life licensed the cethromycin drug from Abbott Laboratories, which has applied for approval in the U.S. and Japan. The drug is one of a class of ketolide antibiotics prescribed to prevent infectious bacteria from becoming resistant to drugs. Advanced Life and Wyeth intend to develop the drug to treat community-acquired pneumonia. (Click here for more